503469-16-7

Basic information

• Product Name: 1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione
• Synonyms: 1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione;1-(1-HYDROXYNAPHTHALEN-2-YL)-3-MORPHOLINOPROPANE-1,3-DIONE;1-(1-Hydroxynaphth-2-yl)-3-(morpholin-4-yl)propan-1,3-dione;Morpholine,4-[3-(1-hydroxy-2-naphthalenyl)-1,3-dioxopropyl]-
• CAS NO: 503469-16-7
• Molecular Formula: C17H17NO4
• Molecular Weight: 299.32118
• Mol File: 503469-16-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione(503469-16-7)
• EPA Substance Registry System: 1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione(503469-16-7)

Safety Data

• Hazardous Substances Data: 503469-16-7(Hazardous Substances Data)

Usage

Description

1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione, also known as HNMPD, is a chemical compound derived from naphthalene with a morpholine group. 1-(1-hydroxynaphthalen-2-yl)-3-Morpholin-4-ylpropane-1,3-dione possesses both hydrophobic and hydrophilic properties due to its unique structure, making it a versatile candidate for pharmaceutical and medical applications. HNMPD has been investigated for its potential therapeutic benefits in treating various medical conditions, such as cancer and neurodegenerative diseases.

Uses

Used in Pharmaceutical Industry:
HNMPD is used as a potential therapeutic agent for the treatment of various medical conditions, including cancer and neurodegenerative diseases. Its unique structure and hydrophobic and hydrophilic properties make it a promising candidate for drug design and development.
Used in Medicinal Chemistry Research:
HNMPD is used as a subject of study in the field of medicinal chemistry, where its potential therapeutic benefits and unique structure are explored for the development of new drugs and treatments for various medical conditions.

Upstream product

• 1696-20-4 4-acetylmorpholine 
• 948-03-8 1-hydroxy-naphthalene-2-carboxylic acid methyl ester 

Downstream Products

• 154447-35-5 2-(morpholin-4-yl)benzo[h]chromen-4-one 

Relevant articles and documents

Selective benzopyranone and pyrimido[2,1-α]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro

A diverse range of chromen-2-one, chromen-4-one and pyrimidoisoquinolin-4- one derivatives was synthesized and evaluated for inhibitory activity against the DNA repair enzyme DNA-dependent protein kinase (DNA-PK), with a view to elucidating structure-activity relationships for potency and kinase selectivity. DNA-PK inhibitory activity varied widely over the series of compounds evaluated (IC50 values ranged from 0.19 to >10 μM), with excellent activity being observed for the 7,8-benzochromen-4-one and pyrimido[2,1-a] isoquinolin-4-one templates. By contrast, inhibitors based on the benzochromen-2-one (coumarin) or 2-aryl-7,8-benzochromen-4-one (flavone) scaffolds were less potent. Crucially, these studies revealed a very constrained structure-activity relationship at the 2-position of the benzopyranone and pyrimido[2,1-a]-isoquinolin-4-one pharmacophore, with only a 2-morpholino or 2-(2′-methylmorpholino) group being tolerated at this position. More detailed biological studies conducted with the most potent inhibitor NU7163 (48; IC50 = 0.19 μM) demonstrated ATP-competitive DNA-PK inhibition, with a Ki value of 24 nM, and 48 exhibited selectivity for DNA-PK compared with the related enzymes ATM, ATR, mTOR, and PI 3-K (p110alpha). Compound 48 sensitized the HeLa human tumor cell line to the cytotoxic effects of ionizing radiation in vitro, a dose modification factor of 2.3 at 10% survival being observed with an inhibitor concentration of 5 μM. This study identified these structural classes as novel DNA-PK inhibitors and delineated initial structure-activity relationships against DNA-PK.